Search

Displaying results 3991 - 4000 of 10000 in total
  1. Drug

    Acteoside

    go.drugbank.com/drugs/DB12996
    Investigational

    Acteoside is under investigation in clinical trial NCT02662283 (Validity and Security of Reh-acteoside Therapy for Patients of IgA Nephropathy).

    Categories: Compounds used in a research, industrial, or household setting
  2. Drug

    Butylated hydroxytoluene

    go.drugbank.com/drugs/DB16863
    Investigational

    Categories: Compounds used in a research, industrial, or household setting
  3. Drug

    Glycocyamine

    go.drugbank.com/drugs/DB02751
    Experimental

    Synonyms: N-amidinoglycine, N-(aminoiminomethyl)glycineCategories: Compounds used in a research, industrial, or household setting
  4. Drug

    Certoparin

    go.drugbank.com/drugs/DB09261
    Approved

    Certoparin is part of the heparins of low molecular weight that presents high activity against the coagulation factor Xa. It is normally used to prevent deep venous thrombosis.

  5. Drug

    GTS-21

    go.drugbank.com/drugs/DB05708
    Investigational

    GTS-21 has been studied in multiple Phase I studies in healthy volunteers and one Phase I/II study in schizophrenic patients. In all studies, the compound was well tolerated. … in human clinical trials.

  6. Drug

    RTA 744

    go.drugbank.com/drugs/DB05920
    Investigational

    RTA 744 is a novel anthracycline derivative that crosses the blood-brain barrier and shows significant potential for the treatment of primary and metastatic brain cancers.

  7. Drug

    RTP-801i

    go.drugbank.com/drugs/DB06048
    Investigational

    RTP-801i is an siRNA drug candidate designed to inhibit the expression of the hypoxia-inducible gene RTP801. … The proposed primary indication for RTP-801i is the treatment of patients with neovascular (wet) Age-related Macular Degeneration (AMD or ARMD).

  8. Drug

    MIV-701

    go.drugbank.com/drugs/DB05736
    Experimental

    MIV-701 is a selective, potent inhibitor of the protease Cathepsin K. It is developed for the treatment of osteoporosis.

  9. Drug

    DG041

    go.drugbank.com/drugs/DB05027
    Experimental

    It block the formation of blood clots mediated through inflammation in atherosclerotic plaques but without increasing bleeding risk. … DG041 is a novel, first-in-class, orally-administered small molecule developmented for the prevention of arterial thrombosis and its complications.

  10. Drug

    Influenza B virus B/Singapore/INFTT-16-0610/2016 antigen (MDCK cell derived, propiolactone inactivated)

    go.drugbank.com/drugs/DB15507
    ApprovedWithdrawn

    Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.